This study highlighted the capacity of PD-L1 to drive immunosuppression, through NLRP3 activation in tumor cells, MDSC recruitment and CD8+ T cells inhibition, without exploring the effects of therapy combining anti-PD-L1 with NLRP3/caspase-1 inhibitor [57]. The gene discussed is CD8A; the disease is neoplasm.